Patent · US Active

Allorestricted peptide-specific T cells

US8633020B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignee

Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · DE

Inventors

Angela Krackhardt · Munich, DE
Ingrid Schuster · Munich, DE
Dirk Busch · Munich, DE

Key dates

Filing date	Jul 9, 2012
Grant date	Jan 21, 2014
Priority date	—
Expiry date	Jul 9, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2239/48
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.